2020
The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelDrug costsCancer CenterLung cancerEpisode costsMean MedicareYale Cancer CenterClinical trial participationSystemic cancer therapyPart D drug costsCancer therapyLower drug costsCommon cancer typesChi-square testPayment modelsClinical factorsNovel cancer therapiesTrial participationOvarian cancerPatient episodesNovel therapiesCare modelCTR groupPharmaceutical costsAlternative payment modelsThe adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapyThe impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.Peer-Reviewed Original ResearchOncology Care ModelDrug costsMean MedicareYale Cancer CenterMean drug costClinical trial participationSystemic cancer therapyLower drug costsCommon cancer typesChi-square testValue-based payment modelsPayment modelsClinical factorsCancer CenterTrial participationLung cancerEpisode costsCare modelCTR groupAlternative payment modelsCancer typesMean differenceCancer therapyCareEpisodes
2018
Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers
Johnson S, Park H, Gross C, Yu J. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e399-e400. DOI: 10.1016/j.ijrobp.2018.07.1180.Peer-Reviewed Original Research